Brief: Alkermes Announces Initiation Of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 For Treatment Of Narcolepsy Type 1

Alkermes

24/04/2024 12:44

April 24 (Reuters) - Alkermes Plc  ALKS.O :
    * ALKERMES ANNOUNCES INITIATION OF VIBRANCE-1 PHASE 2 STUDY
EVALUATING ALKS 2680 FOR THE TREATMENT OF NARCOLEPSY TYPE 1
    * ALKERMES PLC: EXPECTS TO INITIATE VIBRANCE-2, A PLANNED
PHASE 2
STUDY IN PATIENTS WITH NARCOLEPSY TYPE 2, IN SECOND HALF OF 2024

Source text for Eikon:  ID:nPreSfqGPa 
Further company coverage:  ALKS.O 

 ((Reuters.Briefs@thomsonreuters.com;))